[{"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Report from Oregon", "description": "Special report from Karli who is an RN in Oregon.\nKarli promotes local ecology, check out her site, https://www.instagram.com/beetles_and_bees/\nCheck out this one as well, https://www.instagram.com/reel/CG53DqEhBDq/?igshid=bhi7i3cpnvah", "link": "https://www.youtube.com/watch?v=SFfYM6e377s", "date_published": "2021-01-02 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}, {"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "First dose COVID vaccination", "description": "", "link": "https://www.youtube.com/watch?v=LIFqzDQJHuw", "date_published": "2021-01-01 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}, {"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Vaccines, one shot or two?", "description": "Oxford AZ vaccine\n\nhttps://uk.reuters.com/article/uk-health-coronavirus-india-vaccine/astrazeneca-vaccine-set-to-become-first-to-get-approval-in-india-sources-idUKKBN29628Y\n\nIndia approves Oxford vaccine\n\nIndia\u2019s Central Drugs Standard Control Organization (CDSCO)\n\nRollout to start Wednesday\n\nUK\n\nArgentina\n\nIndia\n\nWhat about Europe and the US?\n\nEurope, 400 million does\n\nUS, 300 million doses\n\n\nOn different topic\n\nhttps://news.sky.com/story/covid-19-vaccines-how-do-the-moderna-and-pfizer-coronavirus-jab-candidates-compare-12134062\n\nhttps://www.businessinsider.com/cost-pfizer-astrazeneca-moderna-vaccine-eu-revealed-belgian-mp-2020-12?r=US&IR=T\n\nOxford AstraZeneca $2.18 per dose\n\nPfizer, $20\n\nModerna, $22.06 to $38 per dose\n\n\nWhere is rollout going well\n\nIsrael, 644,000 or 7% so far\n\nBahrain\n\nUK\n\nUS \n\nCanada\n\nEurope\n\n\nOxford/AstraZeneca vaccine\n\nPhase 2 trials\n\n56-day gap\n\nPhase 3 trials\n\nhttps://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32623-4/fulltext\n\nGood immunity with 6-week gap\n\nhttps://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32661-1/fulltext\n\nEfficacy after one dose, 64%\n\nEfficacy after 2 doses, 70 \u2013 80%\n\nCases, 21 days after first SD, 64%\n\nVaccine group, 51 \n\nControl group, 141 \n\nEfficacy 64% \n\nSevere cases 21 days after the first dose of Oxford / AZ\n\nVaccine group, 0\n\nControl group, 10 hospitalised (2 severe, 1 death)\n\n\nCovid-19: Pfizer BioNTech vaccine efficacy was 52% after first dose and 95% after second dose\n\nhttps://www.nejm.org/doi/full/10.1056/NEJMoa2034577?query=RP\n\nhttps://www.bmj.com/content/371/bmj.m4826\n\n\nTwelve days after the first dose\n\nVaccine group, 39 cases\n\nPlacebo group, 82 cases\n\n52% efficacy\n\nSevere cases after one dose\n\nVaccine group, 1\n\nPlacebo group, 9\n\nNew UK vaccine protocol\n\nChange to one dose, second within 3 months\n\nStatement from the UK Chief Medical Officers on the prioritisation of first doses of COVID-19 vaccines\n\nhttps://www.gov.uk/government/news/statement-from-the-uk-chief-medical-officers-on-the-prioritisation-of-first-doses-of-covid-19-vaccines\n\nMedicines and Healthcare products Regulatory Agency (MHRA)\n\nOxford, 2 doses 4 to 12 weeks apart\n\nPfizer, 2 doses 3 to 12 weeks apart \n\nThe Joint Committee on Vaccination and Immunisation (JCVI)\n\nwill protect the greatest number of at risk people overall\n\nin the shortest possible time\n\nand will have the greatest impact on reducing mortality, \n\nsevere disease\n\nand hospitalisations\n\nand in protecting the NHS and equivalent health services.\n\nsecond doses of both vaccines will be administered towards the end of the recommended vaccine dosing schedule of 12 weeks\n\nThe Green Book\n\nhttps://www.gov.uk/government/publications/covid-19-the-green-book-chapter-14a\n\nhttps://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/948757/Greenbook_chapter_14a_v4.pdf\n\nIf an interval longer than the recommended interval is left between doses, the second dose should still be given\n(preferably using the same vaccine as was given for the first dose). \nThe course does not need to be restarted. \nThere is no evidence on the interchangeability of the COVID-19 vaccines although studies are underway. \nTherefore, every effort should be made to determine which vaccine the individual received and to complete with the same vaccine. \nThere is no evidence of any safety concerns from vaccinating individuals with a past history of COVID-19 infection, or with detectable COVID-19 antibody.", "link": "https://www.youtube.com/watch?v=M-jqf6i5OLc", "date_published": "2021-01-01 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}]